- News Releases
It’s the most common form of skin cancer, basal cell carcinoma, and in its advanced stages can become disfiguring and life threatening. For patients with few treatment options, a Mayo Clinic - led study has found that the drug Erivedge (vismodegib) can shrink advanced basal cell carcinoma tumors. The tumors shrank in 43 percent of patients with locally advanced disease and in 30 percent of patients whose disease had spread to other organs.
Lead researcher Aleksandar Sekulic, M.D., Ph.D., a dermatologist and cancer researcher at Mayo Clinic in Arizona says, “This targeted therapy represents a new paradigm in cancer treatment. The findings are very exciting because we haven’t had any therapies before that worked to this degree for advanced basal cell carcinoma.”
Soundbites with Dr. Sekulic are available in the downloads above.
Expert title for broadcast cg:
Dr. Aleksandar Sekulic, Mayo Clinic Dermatologist and Cancer Researcher
Click here for entire news release: DrSekulicNewsRelease2012
March is Colorectal Cancer Awareness Month, which makes this a good time to learn about the risk factors for colorectal cancer and what you can do ...
Mayo Clinic has been taking care of patients with rectal cancer for more than 100 years, dating back to the Mayo brothers. Even at that ...
ROCHESTER, Minn. — March is Myeloma Awareness Month, and Sikander Ailawadhi, M.D., hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center, shares details about new advancements in ...